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Abstract
Binding to the CD4 receptor induces conformational changes in the human immunodeficiency virus (HIV-1) gp120 exterior
envelope glycoprotein. These changes allow gp120 to bind the coreceptor, either CCR5 or CXCR4, and prime the gp41
transmembrane envelope glycoprotein to mediate virus–cell membrane fusion and virus entry. Soluble forms of CD4 (sCD4)
and small-molecule CD4 mimics (here exemplified by JRC-II-191) also induce these conformational changes in the HIV-1
envelope glycoproteins, but typically inhibit HIV-1 entry into CD4-expressing cells. To investigate the mechanism of
inhibition, we monitored at high temporal resolution inhibitor-induced changes in the conformation and functional
competence of the HIV-1 envelope glycoproteins that immediately follow engagement of the soluble CD4 mimics. Both
sCD4 and JRC-II-191 efficiently activated the envelope glycoproteins to mediate infection of cells lacking CD4, in a manner
dependent on coreceptor affinity and density. This activated state, however, was transient and was followed by
spontaneous and apparently irreversible changes of conformation and by loss of functional competence. The longevity of
the activated intermediate depended on temperature and the particular HIV-1 strain, but was indistinguishable for sCD4
and JRC-II-191; by contrast, the activated intermediate induced by cell-surface CD4 was relatively long-lived. The
inactivating effects of these activation-based inhibitors predominantly affected cell-free virus, whereas virus that was
prebound to the target cell surface was mainly activated, infecting the cells even at high concentrations of the CD4
analogue. These results demonstrate the ability of soluble CD4 mimics to inactivate HIV-1 by prematurely triggering active
but transient intermediate states of the envelope glycoproteins. This novel strategy for inhibition may be generally
applicable to high–potential-energy viral entry machines that are normally activated by receptor binding.
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Introduction
The entry of human immunodeficiency virus type 1 (HIV-1) into
target cells is mediated by the trimeric envelope glycoprotein
complex, which consists of three gp120 exterior envelope
glycoproteins and three gp41 transmembrane envelope glycopro-
teins [1]. Binding of gp120 to the receptor, CD4, on the target cell
surface induces major conformational changes in the envelope
glycoproteins [2]. These changes allow gp120 to bind the viral
coreceptor, either CXCR4 or CCR5 [3–7]. CD4 binding also
induces the formation of a gp41 pre-hairpin intermediate, in which
three hydrophobic grooves on the surface of a coiled coil formed by
the heptad repeat 1 (HR1) region of gp41 are exposed [8–10].
These hydrophobic grooves are subsequently occupied by helices
from the gp41 heptad repeat 2 (HR2) region, during the formation
of an energetically stable six-helix bundle that is thought to drive the
fusion of the viral and target cell membranes [9,11,12].
In contrast to the activating effect of cell-surface CD4 on HIV-1
entry, the soluble form of CD4 (sCD4) demonstrates opposing
effects on HIV-1 infectivity at different concentrations. At high
concentrations, sCD4 neutralizes most HIV-1 strains [13]; at
lower sCD4 concentrations, the infectivity of some HIV-1 strains
can be modestly enhanced [14]. This enhancing effect of sCD4 is
more prominent in some strains of the related primate
immunodeficiency viruses, HIV-2 and simian immunodeficiency
virus (SIV), where sCD4 can efficiently replace cell-surface CD4 to
drive infection of CD4
2CCR5
+ cells [15,16].
Based on the potential of sCD4 to inhibit HIV-1 infection in
vitro, this protein was tested for clinical efficacy in HIV-1-infected
individuals; however, no effect on plasma viral loads was observed
[13]. Further examination revealed that doses of sCD4 that were
significantly higher than those achieved in the clinical trial were
required to neutralize primary clinical isolates of HIV-1, in
contrast to the relatively sensitive, laboratory-adapted strains [17].
Interest in improving the therapeutic potential of sCD4 has
prompted investigation of the mechanistic basis for sCD4-induced
neutralization. Competitive inhibition of envelope glycoprotein
binding to the cell-surface CD4 receptor was suggested as a major
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may thus arise by a decreased affinity of the envelope glycoprotein
complex for sCD4 [13]. However, sCD4 sensitivity cannot always
be predicted by measurements of affinity [17,19–21]. Binding of
sCD4 to the envelope glycoprotein trimer can induce detachment
(shedding) of the gp120 subunit from the envelope glycoprotein
trimer [17,18,22–24]. However, the sCD4 concentrations that are
required to elicit shedding are significantly higher than those
required to neutralize the virus [25,26]. In addition, for some
HIV-1 strains, the temperature dependence of sCD4-induced
gp120 shedding and virus neutralization differs [26]. The mode of
sCD4-mediated inhibition thus remains incompletely understood.
Targeting the functionally important and therefore conserved
CD4-binding site on HIV-1 gp120 represents an attractive
potential approach to therapy or prophylaxis. CD4-mimicking
peptides and oligomeric forms of sCD4 that target this site on
primary HIV-1 isolates have been developed [27–30]. Recently, a
new class of small-molecule CD4 mimics was identified [31,32].
These compounds, which include the prototypic compound NBD-
556 and its derivatives, mimic the effects of CD4 by inducing the
exposure of the coreceptor-binding site on gp120 [31,33].
Although NBD-556 inhibits HIV-1 infection of CD4
+CCR5
+
cells, it can replace CD4 and thus enhance HIV-1 infection of
CD4
2CCR5
+ cells [31]. In view of their capacity to enhance
infectivity, any potential application of CD4-mimetic compounds
and sCD4 derivatives, herein referred to as soluble CD4 mimics
(SCMs), would benefit from a mechanistic understanding of these
activating and inhibitory effects.
The study of receptor-induced conformational changes of the
HIV-1 envelope glycoprotein complex is still limited by the lack of
tools that enable monitoring of this dynamic multi-step process.
Detection of conformational intermediates is largely based on the
use of conformation-specific fusion/entry inhibitors, which are
added at different times after initiation of the fusion process [34–
38]. Although such assays have provided insights into the
mechanisms of gp41-directed inhibitors, they fail to detect
transitions to conformations that are inactive and do not
differentiate between lack of inhibitor binding and lack of
inhibition. Furthermore, because formation of the ternary
complex between the envelope glycoproteins, CD4 and coreceptor
constitutes a major rate-limiting step in the membrane fusion
process, these approaches are limited in their capacity to define the
progression of subsequent events [39]. Finally, due to the low
temporal resolution of most systems, mainly steady-state confor-
mations are detected, while intermediate states of the complex
may be missed.
To overcome these limitations, we developed new systems that
allow us to monitor the dynamic changes in conformation and
function of the HIV-1 envelope glycoproteins, immediately after
engagement of the activating molecules. Using these tools, we
found that SCMs inactivate envelope glycoprotein function by an
activation-triggered inhibition process, through induction of a
metastable activated state.
Materials and Methods
Reagents and Antibodies
Four-domain sCD4 (molecular weight 50 kDa) was expressed in
293F cells after stable transfection. The protein was secreted into
the cell culture medium and then purified by using the C-terminal
His6 tag, as previously described [40]. The structure of compound
JRC-II-191 (herein referred to as 191) is reported in reference
[33]. The CCR5 antagonist ‘Compound A’ [4-nitrobenzyl 1-(3-
(N-methylphenylsulfonamido)-3-phenylbutyl)piperidin-4-yl(vinyl)-
carbamate] [41,42] was kindly provided by Dr. Martin Springer
at Merck Research Laboratories, Rahway, NJ.
The anti-gp120 monoclonal antibody 48d, which recognizes an
epitope that overlaps the coreceptor-binding site, was kindly
provided by Dr. James Robinson (Tulane University Medical
Center) [43]. The monoclonal antibodies IgG1 b12 and 39F
recognize the CD4-binding site and the V3 loop of gp120,
respectively [44,45]. The C34-Ig fusion protein consists of the Fc
region of human IgG1 linked to the HR2 region of the HXBc2
envelope glycoprotein (amino acid residues 628–661, numbered
according to current convention [46]). C34-Ig was produced and
purified as previously described [47]. The CD4-Ig fusion protein
consists of the first two N-terminal domains of the CD4 molecule
and the Fc region of human IgG1. Purification was carried out as
described for the C34-Ig molecule [47].
Envelope Glycoprotein Constructs
The primary viruses UK7br and UK7br34 were isolated from
autopsy brain tissue from an AIDS patient with HIV-1 associated
dementia [48]. These envelope glycoproteins were expressed from
the pcDNA 3.1 backbone vector. All other envelope glycoproteins
described were expressed from the pSVIIIenv vector [49]. The
YU2, AD8, JR-FL, 89.6 and KB9 env sequences from Asp 718 (Kpn
I) to BamH I were substituted for the corresponding HXBc2 env
sequences in the original pSVIIIenv vector. The DKS construct,
whichcontains anHIV-1HXBc2 envgene with a large deletion,was
used as a negative control. The YU2(Dct) protein has a truncated
cytoplasmic tail of 17 amino acids, with a stop codon introduced
after Ala 710 (numbered according to current convention [46]).
The YU2-GS8 construct is a cleavage-defective form of the
YU2 HIV-1 envelope glycoproteins that contains an 8-amino acid
glycine-serine linker at the gp120/gp41 junction. Starting with the
cytoplasmic tail-deleted YU2 envelope glycoproteins, both Arg
508 and Arg 511 near the furin cleavage site were altered to Ser to
render the protein cleavage-defective. The 8-amino acid linker,
Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser, was then inserted between Ser
511 (the C-terminal residue of gp120) and Ala 512 (the N-terminal
residue of gp41) using the overlapping PCR method.
Cell-Based Enzyme-Linked Immunosorbent Assay (ELISA)
A sensitive cell-based ELISA with high temporal resolution was
developed to measure the binding of antibodies to HIV-1 envelope
Author Summary
Human immunodeficiency virus type 1 (HIV-1) is the cause
of the global AIDS epidemic. HIV-1 gains entry into its
target cells by fusing with the cell membrane, a process
that begins with the interaction of the viral envelope
glycoproteins with cell-surface receptors. HIV-1 uses two
receptors on the target cell: CD4 and CCR5/CXCR4. Binding
of the virus to the primary receptor, CD4, primes the viral
envelope glycoproteins to mediate the fusion of the viral
membrane and the membrane of the target cell. Soluble
forms of the CD4 receptor and small molecules that mimic
the effects of CD4 can inhibit virus infection; however, how
this inhibition occurs is still unknown. In this report, we
show that soluble mimics of CD4 inhibit HIV-1 infection by
prematurely triggering the viral envelope glycoproteins.
The unstable activated state of the virus lasts only a few
minutes, after which the virus loses the ability to infect
cells. This novel strategy for inhibition may be generally
applicable to other viruses besides HIV-1, some of which
are also activated by binding to their receptors.
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in 96-well plates (2.4610
4 cells per well) and transfected the next
day with 0.1 mg of a plasmid expressing the envelope glycoproteins
and 0.01 mg of a Tat-expressing plasmid per well using the
Effectene transfection reagent (Qiagen). Two days later, cells were
washed twice with blocking buffer (35 mg/ml BSA, 10 mg/ml
non-fat dry milk, 1.8 mM CaCl2, 1 mM MgCl2, 25 mM Tris,
pH 7.5 and 140 mM NaCl). For pulse activation experiments, the
COS-1 cells were incubated with sCD4 (40 mg/ml, 0.8 mM) or
191 (360 mM) suspended in blocking buffer for three minutes,
washed three times with blocking buffer and incubated for
different time periods until the C34-Ig or 48d antibodies were
added (at 40 mg/ml or 1 mg/ml, respectively, for 30 minutes). To
study the temperature dependence of HR1 groove exposure, the
sCD4-pulsed cells were incubated at the requisite temperature for
different lengths of time; the cells were subsequently returned to
room temperature for incubation with C34-Ig. Cells were then
washed four times with blocking buffer and four times with
washing buffer (140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and
20 mM Tris, pH 7.5). A horseradish peroxidase-conjugated
antibody specific for the Fc region of human IgG was then
incubated with the samples for 45 minutes at room temperature.
Cells were washed 5 times with blocking buffer and 5 times with
washing buffer. HRP enzyme activity was determined after the
addition of 33 ml per well of a 1:1 mix of Western Lightning
oxidizing and luminol reagents (Perkin Elmer Life Sciences)
supplemented with 150 mM NaCl. Light emission was measured
with a Mithras LB 940 luminometer (Berthold Technologies). For
experiments that measure the rate of decay of C34-Ig or 48d
antibody binding, the indicated values for the amount of antibody
bound were obtained by subtracting binding measured in the
absence of sCD4 from the binding measured at each time point
after the sCD4 pulse.
HR1 Groove Exposure Induced by Cell-Surface CD4
293T cells cultured in 6-well plates were transfected with the
pcDNA3.1-CD4 or DKS constructs (1 mg per 1.8610
6 cells) using
the Effectene reagent (Qiagen). COS-1 cells cultured in 96-well
plates were transfected with plasmids expressing the HIV-1
envelope glycoproteins as described above. Two days later, the
293T cells were harvested using 5 mM EDTA in PBS and added
at 4uC to the monolayer of COS-1 cells (3610
5 293T cells per
well). Cells were subsequently centrifuged at 1,0006g for two
minutes to increase contact and incubated at 4uC for 75 minutes.
Samples were then washed once with blocking buffer and rapidly
equilibrated to 25uC. C34-Ig was then added at different times.
Detection of C34-Ig binding was performed as described above.
Fluorescence-Activated Cell Sorting (FACS) Analysis of
Ligand Binding to Cell-Surface HIV-1 Envelope
Glycoproteins
Flow cytometry was used to detect the binding of C34-Ig to
293T cells that express the cytoplasmic tail-deleted (Dct) HIV-1
envelope glycoproteins [47]. Cells were cultured in 6-well plates
(1.5610
6 cells per well) and transfected with 0.6 mg of a plasmid
expressing the HIV-1 envelope glycoproteins and 0.06 mgo fa
Tat-expressing plasmid using the Effectene transfection reagent
(Qiagen). Two days later, cells were detached using PBS
supplemented with 5 mM EDTA and resuspendend in FACS
buffer (PBS supplemented with 10 mg/ml BSA and 0.5 mg/ml
sodium azide). Cells were then incubated with C34-Ig suspended
in FACS medium, with or without sCD4, at the indicated
temperature for 45 minutes. Following three washes with FACS
buffer, cells were incubated at room temperature for 45 minutes in
FACS buffer containing a phycoerythrin-conjugated goat anti-
human IgG antibody (Sigma) and an anti-CD4 fluorescein-
conjugated antibody (OKT4, eBioscience) to measure C34-Ig
and sCD4 binding, respectively. Cells were subsequently washed
three times with FACS buffer and analyzed with a FACScan
analyzer (Becton Dickinson) using Cellquest software for data
acquisition and analysis.
Generation and Preparation of Recombinant Luciferase-
Expressing Viruses
Single-round, recombinant HIV-1 viruses that express the
luciferase reporter gene were generated by transfection of 293T
cells using the calcium phosphate transfection method (Promega).
Cells were seeded in 100-mm tissue culture dishes (approximately
4610
6 cells per dish) and transfected the next day with 10 mgo f
the HIV-1 packaging construct pCMVDP1DenvpA [50], 10 mgo f
the firefly luciferase-expressing construct pHIvec2.luc and 2.5 mg
of the plasmid expressing the HIV-1 Rev and envelope
glycoproteins. Sixteen hours following transfection, the medium
was changed to culture medium (Dulbecco-modified Eagle
medium supplemented with 10% fetal calf serum, DMEM/FCS
10%); 12 hours later, the medium was changed to DMEM/FCS
1%. Virus-containing supernatants were collected 12 hours later,
cleared of cell debris by low speed centrifugation and filtered
through 0.2 mm filters. Preparations were subsequently loaded
onto Float-A-Lyzer dialysis cassettes (molecular weight cutoff
100 kDa, Spectrum Labs) and dialyzed against HS buffer
(140 mM NaCl, 10 mM HEPES, pH 7.3) for 24 hours at 4uC.
Viral preparations were subsequently aliquoted and stored at
280uC until use.
Magnetically Controlled Infection by sCD4-Activated HIV-
1
To minimize the time interval between activation of the virus
and attachment to the cells, we magnetically controlled the
attachment step. As a magnetically controllable carrier, we used
magnetite nanoparticles (50 nm in diameter) that are coated by a
starch polymer with phosphate end groups (FluidMag PD,
Chemicell). Viruses were preincubated with magnetite nanopar-
ticles (1.2 mg/ml) for 7 minutes at room temperature, followed by
incubation with sCD4 (40 mg/ml) for different time periods.
Preparations were then added to a confluent monolayer of cells
cultured in a 96-well plate, to which was applied a magnetic field
using a Nd-Fe-B permanent magnet (OZ Biosciences). Canine
thymocyte Cf2Th cells that express CCR5 or both CD4 and
CCR5 were used as target cells (approximately 7610
4 cells per
well). After a one-minute incubation at room temperature, cells
were washed twice with DMEM/FCS 10% and cultured for an
additional 14 hours. Cells were then detached with trypsin-EDTA
and seeded again at a 1:6 dilution. Forty-eight hours after
infection, cells were lysed with passive lysis buffer (Promega) and
lysates were assayed for luciferase activity. To each well was added
100 ml of luciferin buffer (15 mM MgSO4, 15 mM KPO4
[pH 7.8], 1 mM ATP, and 1 mM dithiothreitol) and 50 mlo f
1 mM D-luciferin potassium salt (BD Pharmingen). Luminescence
was recorded using a Berthold LB 960 microplate luminometer.
Decay Rate of Virus Infectivity after Pulse Activation with
sCD4
The decay rate of virus infectivity after activation by sCD4 was
measured using magnetically-immobilized viruses. This method
allows rapid pulsing and washing of the virus before addition of
Metastable Activation of HIV-1 Env
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measured. Virus preparations were preincubated with magnetite
nanoparticles (1.2 mg/ml, suspended in HS buffer) for 7 minutes
and then added to 96-well plates placed over a permanent Ne-Fe-
B magnet (OZ Biosciences). After a 4-minute incubation at room
temperature, wells were washed twice with culture medium.
Immobilized viruses were then pulsed with 40 mg/ml (0.8 mM)
sCD4 for 3 minutes, washed twice with culture medium and then
incubated at room temperature for different time periods. Cf2Th-
CCR5 cells suspended in culture medium (,1610
5 cells) were
then added to the wells and centrifuged at 1,0006g for 2 minutes
to expedite contact between cells and viruses. Luciferase activity
was measured two days later.
Decay Rate of Virus Infectivity after Pulse Activation with
Compound 191
The affinity of NBD-556 analogues, including 191, for the
HIV-1 gp120 envelope glycoprotein is significantly lower than that
of sCD4 [31,33]. Measured by isothermal titration calorimetry,
the Kd of 191 binding to the YU2 gp120 envelope glycoprotein is
760 nM, compared with a Kd of approximately 2 nM for the
sCD4-gp120 interaction. At achievable concentrations, 191
induced significantly lower levels of HIV-1 activation than sCD4
(see Results section); levels of infectivity were consequently too low
to be monitored for decay. We therefore introduced a number of
modifications to the method described above for measuring
infectivity decay. Briefly, viruses were incubated with 180 mM 191
at 37uC for 10 minutes. Activation was then halted by a 20-fold
dilution of the virus-compound mix in HS buffer equilibrated to
26uC. After dilution, no additional activation of HIV-1 infection
was induced by 191 during the time frame of the experiment (data
not shown). Samples were then incubated for different time
periods, associated with magnetite nanoparticles and magnetically
adsorbed to confluent cultures of Cf2Th-CCR5 cells, as described
above.
Infectivity of Cell-Bound Virus Activated by sCD4
Cf2Th cells cultured in 6-well plates (6610
5 cells per well) were
transfected with different amounts of the pcDNA3.1-CCR5
plasmid, which expresses human CCR5, using the Effectene
transfection reagent. Two days later, cells were detached using
5 mM EDTA in PBS and re-seeded in 96-well plates (7610
5 cells
per well). Viruses were then magnetically adsorbed to the
transfected cells in the presence of 20 mg/ml (400 nM) sCD4 in
the culture medium and infectivity was measured two days later.
Results
Rescue of the Infectivity of sCD4-Treated HIV-1 by Rapid
Attachment to Cells
Soluble CD4 mimics (SCMs) can exert varied effects on HIV-1
infection of CD4
+ and CD4
2 target cells. Although soluble CD4
(sCD4) typically inhibits HIV-1 infection of CD4
+CCR5
+ cells,
enhancement of HIV-1 infection of CCR5
+ cells lacking CD4 is
sometimes seen after sCD4 treatment [14]. Sensitivity to these
effects varies among different HIV-1 strains [49]. We examined
the sensitivity to sCD4 of recombinant HIV-1 viruses (designated
HIV-1(AD8) and HIV-1(YU2), respectively) pseudotyped with the
envelope glycoproteins of the primary HIV-1 isolates AD8 and
YU2, which have similar binding affinities for sCD4 [51,52]. In
CD4
+CCR5
+ target cells, sCD4 inhibited the infectivity of HIV-
1(AD8) and HIV-1(YU2) with IC50 values of 80 nM (4 mg/ml)
and 12 nM (0.6 mg/ml), respectively (Figure 1A). In CD4
2CCR5
+
cells, sCD4 activated infection of HIV-1(AD8) much more
efficiently than that of HIV-1(YU2).
A similar pattern of HIV-1 activation and inactivation was
observed for the NBD-556 analogue, JRC-II-191, herein referred to
as 191. The affinity of 191 for the HIV-1YU2 gp120 envelope
glycoprotein (Kd=760 nM) is significantly lower than that of sCD4
(Kd=,2 nM). Nevertheless, at proportionately higher concentra-
tions, 191 resembled sCD4, inhibiting HIV-1 infection of
CD4
+CCR5
+ cells and enhancing infection of CD4
2CCR5
+ cells
(Figure 1B). For both sCD4 and 191, the enhancement of infection
of cells lacking CD4 became progressively less efficient at higher
concentrations; in some cases, decreases in viral infectivity were
associated with escalating doses. These characteristics of HIV-1
envelope glycoproteins differ from those observed with several SIV
envelope glycoproteins, which demonstrate increasingly efficient
infection of CD4
2CCR5
+ cells with increasing sCD4 concentra-
tions (data not shown, and ref. [15]). These observations suggested
the existence of a concentration-dependent, virus-inhibitory process
superimposed on the HIV-1 activation process.
Because virus attachment to cells in culture progresses in a slow,
diffusion-dependent manner [53,54], significant time intervals can
elapse between virus binding by SCMs and the association
between virus and cell. Thus, the diminished capacity of the SCMs
Figure 1. Inhibition and activation of infection by sCD4 and the CD4-mimetic compound 191. Recombinant HIV-1(YU2) or HIV-1(AD8)
strains were incubated with CD4
2CCR5
+ or CD4
+CCR5
+ Cf2Th cells for 48 hours in the presence of sCD4 (A) or 191 (B). Infectivity was determined by
measurement of luciferase activity. (C) HIV-1(YU2) was incubated for three minutes in the presence or absence of sCD4 (40 mg/ml, 0.8 mM) and then
adsorbed by diffusion or magnetically to cultures of the indicated cell type. Measured luciferase activity is presented as mean relative light units
(RLU)6standard error of the mean (s.e.m.) of three replicate samples.
doi:10.1371/journal.ppat.1000360.g001
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2CCR5
+ cells at higher
concentrations might reflect the involvement of time-dependent as
well as concentration-dependent processes that abrogate infectivity
after activation occurs. To test this possibility, we examined the
effect of neutralizing concentrations of sCD4 on HIV-1(YU2)
infection when the time interval between sCD4-virus binding and
virus-cell attachment was reduced. For this purpose, we applied a
system that magnetically controls virus motion to eliminate viral
dependence on passive diffusion for cell attachment; this system
allows near-complete transfer of the virus inoculum to the cell-
bound state within one minute [53,55]. When HIV-1(YU2) was
briefly incubated with a high concentration of sCD4 and then
added to CD4
2CCR5
+ cells, infection occurred only when the
virus was magnetically adsorbed to the cells (Figure 1C). These
results suggested the possibility of a time-dependent process that
decreases HIV-1 infectivity after activation by sCD4, and
prompted us to measure the stability of the sCD4-activated
intermediate form of the HIV-1 envelope glycoproteins.
Conformational Stability of the CD4-Activated
Intermediate
Engagement of CD4 induces a major structural rearrangement
of the HIV-1 envelope glycoproteins [2]. Two functionally
important regions of the HIV-1 envelope glycoproteins are formed
and exposed as a result of CD4 binding: i) the coreceptor-binding
site on the gp120 envelope glycoprotein [3–7,56]; and ii) the
trimeric coiled coil composed of the N-terminal heptad repeat
(HR1) regions of the three gp41 subunits [8–10,47]. To investigate
the conformational stability of the sCD4-activated envelope
glycoprotein intermediate, we monitored changes over time in
the exposure of the coreceptor-binding site on gp120 and the HR1
coiled coil on gp41 after pulse activation by sCD4.
To measure the progression of conformational changes that
immediately follow HIV-1 envelope glycoprotein activation, we
developed a novel enzyme-linked immunosorbent assay (ELISA)-
based system that utilizes live cells as a platform for expression of
membrane-bound trimeric envelope glycoprotein complexes The
system allowed sensitive detection of ligand binding to full-length
envelope glycoproteins at high temporal resolution. COS-1 cells
that express the HIV-1YU2 envelope glycoproteins were pulse-
activated with sCD4 at 37uC for 3 minutes and incubated at 37uC
for different time periods. The following probes were then added:
i) monoclonal antibody 48d, which binds to a gp120 epitope that
overlaps the coreceptor-binding site [43]; or ii) the C34-Ig protein,
which is composed of the C34 peptide corresponding to the gp41
HR2 region linked to the Fc constant region of human IgG1 [47].
C34-Ig binds to the hydrophobic groove formed at the interface of
the HR1 coiled-coil helices [10,47]. The sCD4 pulse significantly
enhanced the binding of the C34-Ig protein and the 48d antibody
to the HIV-1 envelope glycoproteins (Figure 2A and 2B). The time
interval between the sCD4 pulse and addition of the 48d antibody
did not affect the level of 48d binding observed (Figure 2B). Thus,
after the sCD4-induced conformational change, the epitope of the
48d antibody remains stably exposed over the time period
examined.
In contrast to the above results, the exposure of the C34-Ig
binding site after the sCD4 pulse was transient at 37uC (Figure 2C).
Stability of the HR1-exposed state was highly dependent on the
temperature of incubation (Figure 3A). Although sCD4 efficiently
bound to the envelope glycoprotein complex and induced the
formation/exposure of the HR1 groove at 4, 25 and 37uC, this
state was stable only at lower temperatures (Figure 3B). The loss of
exposure of the HR1 groove was not reversible by repeated
pulsing of the envelope glycoprotein complexes with saturating
concentrations of sCD4 (data not shown). At the different
temperatures examined, in the absence of sCD4, C34-Ig binding
was similar to that measured for the negative control cells
transfected with the DKS plasmid. No correlation was observed
between the temperature of incubation and the binding of C34-Ig
in the absence of sCD4.
Given the constant level of 48d antibody binding to the sCD4-
pulsed envelope glycoprotein-expressing cells, the observed time-
dependent decrease in C34-Ig binding cannot be attributed to
changes in cell-surface levels of the envelope glycoproteins, as
might occur due to gp120 shedding [17]. Moreover, we observed
that sCD4 binding to the cells remained constant over the time
period examined. We performed a kinetic experiment to measure
the decay of HR1 exposure using FACS analysis. The binding of
sCD4 and C34-Ig to the envelope glycoprotein-expressing cells
was measured simultaneously at different time points after the
sCD4 pulse, using phycoerythrin- and fluorescein-conjugated
secondary antibodies. We observed a gradually decreasing
capacity of C34-Ig to bind despite constant levels of bound
sCD4 (Figure S1).
In summary, after engagement of sCD4, the HIV-1 envelope
glycoprotein complex undergoes conformational changes that
result in formation/exposure of the gp120 coreceptor-binding site
and the gp41 HR1 groove. However, despite continued
engagement of sCD4 and stable exposure of the 48d epitope on
gp120, the induced envelope glycoprotein intermediate undergoes
a spontaneous temperature-dependent and apparently irreversible
change of conformation.
Decay of Exposure of the HR1 Groove on Envelope
Glycoproteins from Different HIV-1 Strains
The decay profile of sCD4-induced HR1 groove exposure was
determined for a panel of envelope glycoproteins from primary and
laboratory-adapted HIV-1 strains. Measurements were conducted
at room temperature (24–26uC) to slow the rate of decay, allowing
greater accuracy. Interestingly, a wide range of stabilities of the
HR1 groove-exposed state was observed in the different HIV-1
envelopeglycoproteins(Figure 4A). For example,theYU2and AD8
envelope glycoproteins exhibited half-lives of 5 and 100 minutes,
respectively. The different decay rates of HR1 groove exposure
could not be explained by differences in the affinity of the trimeric
envelope glycoprotein complexes for sCD4 (Figure S2A), or in
kinetic differences in CD4-Ig binding to these complexes (Figure
S2B). We also found that the deletion of the gp41 cytoplasmic tail
had no effect on the stability of the CD4-activated intermediate
(Figure S2C), even though the cell-surface level of envelope
glycoprotein expression was increased, as expected [57].
Envelope glycoproteins from HIV-189.6 and HIV-1KB9 exhib-
ited highly stable sCD4-induced intermediates that did not
appreciably decay at room temperature for up to 1 hour after
the sCD4 pulse. For these envelope glycoproteins, the half-lives of
the HR1-exposed state measured at 37uC were 16 and
17 minutes, respectively (Figure S2D).
Correlation between Stability of the HR1 Groove and
Functional Stability of the HIV-1 Envelope Glycoproteins
after sCD4 Exposure
Does the sCD4-induced conformational instability in the HIV-1
envelope glycoproteins have consequences for virus infectivity? To
examine this question, we devised a strategy to measure changes
over time in the capacity of sCD4-activated virus to infect
CD4
2CCR5
+ cells. First, recombinant, luciferase-expressing
viruses were associated with magnetite nanoparticles and immo-
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magnetic field. Next, the immobilized viruses were pulsed with
sCD4 for 3 minutes and incubated at 25uC for different time
periods. Then, CD4
2CCR5
+ cells were added and immediately
pelleted onto the immobilized viruses. Infectivity was assessed by
measuring luciferase activity in the cells 48 hours later. The levels
of initial infectivity for viruses pseudotyped with the different HIV-
1 envelope glycoproteins were significantly increased by incuba-
tion with sCD4 (data not shown). However, infectivity subse-
quently declined at different rates for viruses with different
envelope glycoproteins (Figure 4B). Similar to the stability of HR1
groove exposure, the rate of decay of infectivity was highly
dependent upon temperature (Figure S3). At room temperature,
the half-life of infectivity exhibited by the sCD4-treated viruses
pseudotyped with different HIV-1 envelope glycoproteins corre-
lated well with the half-life of the HR1 groove-exposed state
following incubation with sCD4 (R
2=0.9374, Figure 4C).
Assuming that the linear regression model generated using the
data obtained at 25uC applies to the situation at 37uC, we first
estimated the half-lives of HIV-1 infectivity by fitting the half-lives
of HR1 groove exposure measured at 37uC to the model. For the
most stable envelope glycoproteins (derived from HIV-189.6 and
HIV-1KB9), we estimated a maximal half-life of infectivity of 5–
7 minutes at 37uC. In accordance with the predicted values, the
measured half-lives of infectivity at 37uC for viruses containing the
KB9 and 89.6 envelope glycoproteins were 7 and 8 minutes,
respectively, after the sCD4 pulse (Figure S2E).
We compared the infectious half-lives of viruses with different
HIV-1 envelope glycoproteins following incubation with sCD4
(using CD4
2CCR5
+ cells, as described above) and without sCD4
treatment (using CD4
+CCR5
+ cells). Incubation of the viruses at
37uC for increasing time periods in the absence of sCD4, followed
by infection of CD4
+CCR5
+ cells, revealed a gradual reduction of
infectivity, with half-lives ranging from 6.9 to 12.1 hours (Figure
Figure 2. Soluble CD4-induced changes in the gp120 coreceptor–binding region and gp41 HR1 region. (A) A cell-based ELISA was used
to measure the binding of C34-Ig, which detects the HR1 gp41 region [38,47], to the trimeric HIV-1 envelope glycoproteins. COS-1 cells were
transfected with the negative control DKS plasmid or plasmids expressing the full-length YU2 envelope glycoproteins (left) or the cytoplasmic tail-
deleted (Dct) YU2 envelope glycoproteins (right). Two days later, cells were incubated with C34-Ig (20 mg/ml), in the presence or absence of sCD4
(20 mg/ml). C34-Ig binding was measured using a secondary horseradish peroxidase-conjugated antibody. (B,C) Change over time in the exposure of
CD4-induced epitopes. Cells that express the YU2(Dct) envelope glycoproteins were pulsed for three minutes with sCD4 (40 mg/ml). Cells were then
washed three times and incubated for different time periods at 37uC. The monoclonal antibody 48d (B) or C34-Ig (C) was then added. The bound 48d
or C34-Ig molecules were detected using a horseradish peroxidase-conjugated anti-human IgG Fc antibody, as described in Materials and Methods.
Values represent the mean RLU (6s.e.m.) of two replicate samples.
doi:10.1371/journal.ppat.1000360.g002
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the native and sCD4-bound states of each of the envelope
glycoproteins was observed.
We conclude that after engagement of sCD4, HIV-1 undergoes
a transient phase of activation, during which attachment to cells
that express CCR5 will allow entry to occur. However, this
activated state is short-lived and is followed by apparently
irreversible structural rearrangements and loss of infectivity. Thus,
at any given time point after exposure to sCD4, HIV-1 infectivity
represents the combined result of an activation process and
progression through the activated intermediate state to inactiva-
tion (Figure S5).
Figure 3. Temperature dependence of the decay of HR1 groove
exposure. (A) Decay of HR1 groove exposure at different temperatures
after pulse activation with sCD4 (40 mg/ml; 0.8 mM) was measured by a
cell-based ELISA, as described in Materials and Methods. The indicated
values for C34-Ig binding were obtained by subtracting the values of
C34-Ig binding in the absence of sCD4 from the binding measured at
each time point after the sCD4 pulse. Mean background levels of C34-Ig
binding (in the absence of sCD4) were 10316, 21413, and 19028 RLU for
the experiments performed at 4uC, 25uC, and 37uC, respectively. (B)
Binding of C34-Ig and sCD4 to the HIV-1 envelope glycoproteins was
measured at different temperatures. Cells that express the YU2(Dct)
envelope glycoproteins were incubated simultaneously with both C34-
Ig (20 mg/ml) and sCD4 (20 mg/ml; 0.4 mM) at the indicated tempera-
ture. Binding of sCD4 and C34-Ig was detected by FACS analysis using a
fluorescein-conjugated anti-CD4 antibody and a phycoerythrin-conju-
gated goat anti-human IgG antibody, respectively (see Materials and
Methods). The mean fluorescence intensity (MFI) of the cells in both
channels is shown.
doi:10.1371/journal.ppat.1000360.g003
Figure 4. Relationship between infectivity decay and loss of
HR1 groove exposure. (A) Decay of HR1 groove exposure of different
HIV-1 envelope glycoproteins was studied at 25uC after pulse activation
with sCD4. COS-1 cells expressing the indicated HIV-1 envelope
glycoproteins were pulsed with sCD4 (40 mg/ml; 0.8 mM) for 3 minutes,
followed by assessment of HR1 groove exposure using the cell-based
ELISA method, as described in the Figure 2 legend. (B) Recombinant
HIV-1 virions carrying the indicated envelope glycoproteins were pulsed
with sCD4 (40 mg/ml; 0.8 mM) for 3 minutes and incubated at 25uC.
After the indicated times, CD4
2CCR5
+ Cf2Th cells were added to the
viruses. For the sample marked as control, HIV-1(YU2) was pulsed with
buffer and then CD4
+CCR5
+ cells were added. Two days later, virus
infectivity was assessed by measuring luciferase activity in the target
cells. (C) The relationship between the decay rate of HR1 groove
exposure and the decay rate of infectivity, both measured at 25–27uC
after pulse activation with sCD4, is shown for the panel of HIV-1
envelope glycoproteins. Half-lives were determined by fitting a model
function to the data using nonlinear regression. Values represent half-
lives (6s.e.m. for both variables) derived from two to four separate
experiments for each envelope glycoprotein variant.
doi:10.1371/journal.ppat.1000360.g004
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Mimic
CD4-mimetic compounds exemplified by NBD-556 and 191
induce conformational changes in the HIV-1 envelope glycopro-
teins similar to those induced by sCD4 [31,33]. These changes
include formation/exposure of both the coreceptor-binding site on
gp120 and the HR1 groove on gp41 (Figure 5). The similarity
between the effects of 191 and sCD4 on HIV-1 infection of CD4
+
and CD4
2 cells (Figure 1) suggested that 191 may also induce
transiently activated intermediate states in the HIV-1 envelope
glycoproteins. To examine this possibility, we compared the decay
profiles associated with sCD4 and 191. We examined the YU2
and AD8 envelope glycoproteins, which exhibit dramatic
differences in the decay rate of the sCD4-induced intermediate.
For each of these envelope glycoproteins, sCD4 and 191 induced
identical decay profiles, both for HR1 groove exposure and for
infectivity (Figure 6). These results suggest that sCD4 and 191
induce a similar, transient intermediate state in the HIV-1
envelope glycoproteins. Moreover, the differences in decay rates
between the AD8 and YU2 envelope glycoproteins were evident
for both sCD4 and 191, suggesting that the stability of the induced
state is determined by intrinsic properties of the envelope
glycoproteins rather than by the activating agent.
A More Stable Envelope Glycoprotein Intermediate
Induced by Cell-Surface CD4
To examine the longevity of the activated intermediate induced
during the normal HIV-1 entry process, we examined the stability
of HR1 groove exposure after the binding of the envelope
glycoproteins to cell-surface CD4. For this purpose, 293T cells that
express CD4 (but not CCR5) were used to activate the HIV-1
envelope glycoproteins expressed on COS-1 cells. Pilot experi-
ments demonstrated that the observed increases in C34-Ig binding
to the envelope glycoproteins-expressing cells depended on the
presence of CD4 on the activating cell, and were not observed for
a mutant envelope glycoprotein (YU2-GS8), which binds CD4
efficiently but does not expose the HR1 groove in response (see
Figure S6 and Materials and Methods). Relative to the effects of
treatment with sCD4 or 191, the HR1 groove exposure
consequent to activation by cell-surface CD4 was surprisingly
long-lived (Figure 7A). The AD8 and YU2 envelope glycoproteins,
which exhibited significant differences in the half-lives of HR1
groove exposure after activation by sCD4, both formed stable
intermediates following activation by cell-surface CD4.
During HIV-1 entry, CCR5 binding to the CD4-induced
envelope glycoprotein intermediate promotes progression along
the path to virus entry [58]. Differences in the longevity of the
CD4-induced state would be predicted to manifest themselves as
an altered dependency on the density of target cell CCR5. To test
this, the CCR5 available on CD4-expressing cells for interaction
with the HIV-1 envelope glycoproteins was varied in two ways: 1)
the addition of increasing amounts of Compound A, a CCR5
inhibitory compound [41,42,59], to cells expressing both CD4 and
CCR5; and 2) transfection of different amounts of a CCR5-
expressing plasmid into cells expressing CD4. The latter method is
based on the direct relationship between the amount of CCR5
DNA transfected and the cell-surface density of the expressed
Figure 5. Effect of compound 191 on exposure of the gp41 HR1
groove. COS-1 cells transfected with a plasmid expressing the
YU2(Dct) envelope glycoproteins or with the control DKS plasmid,
which does not express an envelope glycoprotein on the cell surface,
were incubated with the indicated molecules in the presence or
absence of C34-Ig (20 mg/ml). The data represent the means (6s.e.m.)
of two replicate samples.
doi:10.1371/journal.ppat.1000360.g005
Figure 6. Longevity of the HIV-1 envelope glycoprotein intermediate at room temperature after activation by sCD4 or 191. (A) The
decay of HR1 groove exposure for cell-surface–expressed YU2 and AD8 envelope glycoproteins is compared after pulse activation with 191 (360 mM)
or sCD4 (40 mg/ml, 0.8 mM). (B) The decay of the ability to infect CD4
2CCR5
+ Cf2Th cells after pulse activation with 191 or sCD4 is compared.
doi:10.1371/journal.ppat.1000360.g006
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1(AD8) or HIV-1(YU2) and the efficiency of infection measured.
HIV-1(AD8) and HIV-1(YU2) behaved indistinguishably in
response to variations in the CCR5 available on target cells
expressing CD4 (Figure 7B and 7C). In contrast, when sCD4 was
used to activate infection of Cf2Th cells expressing different levels
of CCR5, entry by HIV-1(AD8) was significantly better than that
of HIV-1(YU2) (Figure 7D). These results are consistent with the
existence of a relatively long-lived envelope glycoprotein interme-
diate being induced by CD4 expressed on the target membrane.
Discussion
Clinical testing of the inhibitory efficiency of sCD4 revealed no
reduction of viral loads in HIV-1-infected individuals [13]. Failure
of treatment was attributed to the resistance to sCD4-mediated
inhibition of primary HIV-1 isolates, relative to laboratory-
adapted isolates [13]. However, lower sCD4-binding affinity could
not be consistently correlated with resistance of HIV-1 isolates to
inhibition [17,19]. Furthermore, in vitro observations of sCD4-
mediated enhancement of infection [14] remained largely
unexplained. More recently, small-molecular-weight compounds
have been developed that target the highly conserved CD4-
binding site of the gp120 envelope glycoprotein [31,32]. NBD-556
and its derivatives bind to the gp120 envelope glycoprotein and
induce structural changes similar to those promoted by sCD4.
Although currently NBD-556 and analogues are only interesting
tools to study the entry process, with improvement, they could
prove useful therapeutically or prophylactically. However, in view
of their potential to enhance HIV-1 infection, an understanding of
the mechanisms underlying the effects of SCMs is essential for the
safe application of these inhibitors.
In this study, we apply a new approach to define the dynamics of
conformational changes that occur in the trimeric membrane-
bound form of the HIV-1 envelope glycoproteins. The binding of
conformation-specific probes was directly measured at high
temporal resolution, allowing us to monitor transiently exposed
structures and thus to define the longevity of specific activated
intermediates. The lack of dependence on indirect methods, such as
the use of conformation-specific inhibitors, and the capacity to
detect conformational intermediates permitted identification of an
SCM-induced transitionto the inactive state. In contrast to previous
observations based on the interactions of envelope glycoprotein-
and receptor-expressing cells [26,60], we detected no lag in the
formation/exposure of either the gp120 coreceptor-binding site or
the gp41 HR1 groove, two key signatures of the SCM-activated
state. Even at low temperatures, both sites were immediately
exposed after binding of the SCMs to gp120. This is consistent with
a model in which conformational changes in the envelope
glycoproteins associated with SCM binding are tightly coupled, or
perhaps coincide, with the structural transitions that shape and
expose the coreceptor-binding site and the HR1 coiled coil.
Except for its lower affinity for the envelope glycoproteins, the
NBD-556 analogue 191 [31,33] exerted effects that were
remarkably similar to those exerted by sCD4. Thus, the properties
of the SCM-induced intermediate defined in this study are
intrinsic to the envelope glycoproteins of the particular HIV-1
strain rather than being dependent on the individual SCMs.
During HIV-1 infection of CD4
+ cells, SCMs compete for cell-
associated CD4. Competition for the cell-surface CD4 receptor
was previously suggested as a major mechanism of HIV-1
inhibition by sCD4 [17,18]. In this work, we show that SCMs
can efficiently substitute for cell-surface CD4. In this context, some
inhibition of infection may result from the difference in the
efficiency with which membrane-anchored CD4 and SCMs
promote HIV-1 entry. Importantly, we demonstrate that SCMs
inhibit HIV-1 infection by a novel mechanism that is initiated by
activation of the viral envelope glycoproteins. Similar to the
envelope glycoprotein intermediate that results from binding cell-
surface CD4, the SCM-induced activated state is characterized by
the exposure of the coreceptor-binding site on gp120 and the HR1
groove on gp41. Moreover, the SCM-activated envelope glyco-
proteins are able to mediate virus entry into CCR5
+ cells lacking
CD4. However, in contrast to the stable activation induced by cell-
surface CD4, the SCM-activated intermediate decays rapidly, in a
manner dependent upon temperature and envelope glycoprotein
Figure 7. HIV-1 activation by native CD4 and sCD4. (A) The stability of HR1 groove exposure was measured after activation of the YU2 or AD8
envelope glycoproteins by cell-surface CD4. Background was defined as C34-Ig binding to cells transfected with the YU2-GS8 construct, which
engages sCD4 with an affinity similar to that of the wild-type YU2 envelope glycoproteins but does not expose the HR1 groove (see Figure S6). The
background was subtracted from all measurements, which are presented as percent (6s.e.m.) of C34-Ig binding measured at the initial time point. (B)
The effect of the CCR5 antagonist ‘‘Compound A’’ [41,42] on infectivity of recombinant HIV-1 pseudotyped with the indicated envelope glycoproteins
was investigated. Cf2Th-CD4/CCR5 cells were infected with HIV-1(AD8) or HIV-1(YU2) in the presence of increasing concentrations of Compound A.
Data are presented as the percentage (6s.e.m.) of infection measured in the absence of the compound. (C) The effect of CCR5 expression on the
infection of CD4-expressing cells by HIV-1(AD8) or HIV-1(YU2) was examined. Cf2Th-CD4 cells were transfected with different amounts of a plasmid
that expresses human CCR5. Two days later, transfected cells were incubated with HIV-1(AD8) or HIV-1(YU2). Infectivity is expressed as the
percentage (6s.e.m.) of infectivity measured for cells transfected with the highest amount of the CCR5-expressing plasmid. (D) The graph shows
infection by cell-bound virus of CD4
2 Cf2Th cells transfected with different amounts of the CCR5-expressing plasmid in the presence of 20 mg/ml
sCD4. Infectivity is expressed as the percentage (6s.e.m.) of infection measured in cells transfected with plasmids expressing CD4 and CCR5 (0.6 and
0.9 mg, respectively, of each plasmid per well).
doi:10.1371/journal.ppat.1000360.g007
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membrane-fusing potential are irreversibly lost.
The SCM-induced exposure of the hydrophobic HR1 groove
may be energetically unfavorable in the context of free virus,
favoring a transition to a more stable but nonfunctional state.
Whether this nonfunctional state involves a prematurely triggered
six-helix bundle in gp41 or another, possibly off-pathway,
conformation requires further investigation. Arguing against the
former possibility is the expectation that six-helix bundle
formation in gp41 would be incompatible with maintaining the
non-covalent association with gp120. In fact, even for the most
unstable envelope glycoprotein intermediate studied, no evidence
of gp120 shedding after SCM treatment was observed. Despite
rapid loss of function, the SCM-inactivated envelope glycoproteins
retained gp120, which remained associated with the SCM and
stably attached to the expressing cell surface. This finding is
consistent with previous studies of dose response, temperature
dependence, timing and HIV-1 strain specificity that show a lack
of correlation between the HIV-1-inhibitory activity of sCD4 and
the degree of gp120 shedding induced [14,17,19,21,25].
By contrast, the kinetics of the decay of SCM-induced HR1
groove exposure and the decay of HIV-1 infectivity correlate, and
the ranges of SCM concentrations required for induction of the
labile envelope glycoprotein intermediate and for virus neutrali-
zation overlap. These observations support the important
contribution that induction of the metastable activated interme-
diate makes to SCM-mediated inhibition of virus infectivity.
Achieving inhibition by initiating the targeted process is unusual,
but two properties of the HIV-1 envelope glycoproteins render
them susceptible to this strategy of inhibition: 1) initial folding and
assembly into a high-potential-energy form that is prone to
transform into energetically more favorable states; and 2)
triggering of these conformational transitions by receptor binding,
allowing a receptor mimic to take advantage of the built-in
propensity of the viral envelope glycoproteins to engage the
receptor and undergo global conformational changes.
The efficiency of an activation-based mechanism of inhibition is
determined by the change over time in the distribution of the
HIV-1 envelope glycoproteins among three states: 1) unliganded/
non-activated; 2) bound/activated; and 3) post-activation decayed.
This distribution is influenced by the following factors: 1) rate of
SCM engagement; 2) the time interval between SCM-induced
activation and progression to a step of infection that is unaffected
by the decay process; and 3) the intrinsic stability of the SCM-
induced activated intermediate. Forces that determine the
distribution between these three states dictate the balance between
enhancement and inhibition of infection, as detailed below.
Infection by cell-free virus is rate-limited by the slow diffusion-
dependent attachment of the virus to the cell surface [53,54].
Activation of the diffusing virus by a soluble molecule is thus
characterized by an extended lag period between activation and
the next step of the infection sequence. Half-maximal productive
adsorption of diffusing HIV-1 virions to a cell monolayer (i.e.,
attachment that culminates in an infection event) occurs after
approximately 5 hours at 37uC [55]. By contrast, the half-life of
infectivity of the most stable activated intermediate examined in
this study at 37uC was less than 8 minutes. As the longevity of the
SCM-activated intermediate is significantly shorter than the
duration of the attachment step, SCM-mediated inhibition of
cell-free virus is primarily determined by the rate of activation (i.e.
by both the on-rate and effective concentration of the compound).
Activating effects on HIV-1 infection predominate at low
concentrations of SCMs. The dependence of virus activation and
inactivation on SCM concentration was particularly evident in the
biphasic dose-effect curves associated with HIV-1(YU2) infection
of CD4
2 CCR5
+ target cells (Figure 1A and 1B and Figure S5).
The stoichiometry of SCM binding to the HIV-1 envelope
glycoprotein trimers may influence the propensity of the activated
intermediate(s) to proceed along entry or post-activation decay
pathways. For example, the binding of two SCMs to the envelope
glycoprotein trimer may be more efficient in promoting inactiva-
tion/decay than the binding of a single SCM. Such a model would
explain the exceptionally long-lived sCD4 activation of SIV
[15,61], the envelope glycoproteins of which have been reported
to bind only one CD4 molecule per trimer [62,63].
Retrovirus transmission is significantly more efficient when virus
is transferred through direct physical interaction between cells
(cell-cell transmission) than by diffusion of virions in cell-free
transmission [64]. During cell-cell transmission, where HIV-1
virions emerging from the infected cell rapidly achieve proximity
to the target cell [65,66], SCMs are more likely to enhance
infection than in the case of cell-free infection. Indeed, HIV-1 that
was pre-bound to the surface of CD4
2CCR5
+ cells, perhaps
mimicking the conditions of cell-cell transmission, infected the cells
efficiently after incubation with SCM concentrations that were
highly neutralizing for cell-free virus. In cell-cell transmission, the
time interval between SCM-induced activation and the next step
committed to the infection pathway exerts a dominant influence
on the efficiency of HIV-1 inhibition by SCMs. Several
observations suggest that the engagement of the coreceptor plays
a major role in moving the SCM-activated HIV-1 envelope
glycoproteins along the entry pathway. First, the sCD4-mediated
enhancement of HIV-1 infection of CD4
2 cells is highly
dependent on the level of CCR5 expression (Figure 7D). Second,
a study of activation of infection of CD4
2CCR5
+ cells by NBD-
556 indicated a contribution of CCR5-binding affinity to
susceptibility to enhancement [33]. Finally, although SCMs
allowed CCR5-using viruses to infect CD4
2CCR5
+ cells, SCMs
did not stimulate the infection of CD4
2CXCR4
+ cells by
CXCR4-using viruses. The lack of enhancement of CXCR4-
using viruses was not due to greater lability of the activated state.
The half-life of the sCD4-induced, HR1-groove-exposed state on
the CXCR4-tropic HXBc2 envelope glycoproteins was 55 min-
utes at 26uC, and was significantly longer on the dual-tropic KB9
envelope glycoproteins. Despite this, neither of these envelope
glycoproteins supported infection of CD4
2CXCR4
+ cells after
incubation with sCD4 or 191 [ref. 33 and data not shown].
However, 191 did allow viruses with the KB9 envelope
glycoproteins to infect CD4
2CCR5
+ cells. The apparent inability
of SCM-activated viruses to utilize CXCR4 for entry may be a
consequence of the significantly lower affinity of CXCR4 for the
HIV-1 envelope glycoproteins, relative to that of CCR5 [67].
Together, these observations support the importance of efficient
coreceptor binding to the susceptibility of HIV-1 to SCM-induced
activation of infection of CD4
2 cells. Further work will be
required to assess whether this type of enhancement can occur on
primary CD4
2CCR5
+ cells following SCM treatment.
The mechanism of inhibition elucidated here suggests that
SCMs will be most effective in settings, such as sexual
transmission, in which HIV-1 is fully dependent on diffusion for
successful infection. Efforts to develop small-molecule SCMs with
improved rates of engaging the HIV-1 envelope glycoproteins are
therefore warranted.
Binding of the HIV-1 envelope glycoproteins to native,
membrane-anchored CD4 resulted in the stable exposure of the
HR1 groove on gp41, in contrast to the labile structure induced by
SCMs. Although additional studies will be needed to address the
basis of this difference, our data rule out the contribution of CCR5
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HIV-1 envelope glycoprotein intermediate induced by cell surface
CD4 facilitates engagement of additional CD4 molecules and the
coreceptor, and creates a ‘‘window of opportunity’’ for inhibition
of downstream events in virus entry.
Supporting Information
Figure S1 Decay of HR1 groove exposure measured by FACS.
Cells that express the YU2(Dct) envelope glycoproteins were
incubated at room temperature with sCD4 (40 mg/ml; 0.8 mM) for
20 min, washed, and further incubated at room temperature for
the indicated time periods. Then the C34-Ig protein (40 mg/ml)
was added. Binding of sCD4 and C34-Ig was detected by
fluorescein- and phycoerythrin-conjugated antibodies, respective-
ly, as described in the Figure 3 legend. Note that the decrease in
the mean fluorescence intensity of C34-Ig binding (right panel) was
more modest than the decrease in the percentage of the double-
positive cell population.
Found at: doi:10.1371/journal.ppat.1000360.s001 (0.44 MB TIF)
Figure S2 The kinetics, affinity, and consequences of soluble
CD4 binding to the HIV-1 envelope glycoproteins. (A) Binding of
sCD4 to the YU2 and AD8 envelope glycoprotein complexes on
the surface of expressing cells was examined. COS-1 cells
expressing the YU2 and AD8 full-length envelope glycoproteins
were incubated with the indicated concentrations of sCD4 for 1 h
at room temperature. Cells were then washed four times and
incubated with the anti-CD4 monoclonal antibody OKT4 (10 mg/
ml) for 30 min. Cells were subsequently washed, and binding was
detected using a horseradish peroxidase-conjugated goat-anti-
mouse polyclonal antibody. Results are presented as mean RLU
(6s.e.m.) of two replicate samples. (B) The kinetics of CD4-Ig
binding to full-length YU2 and JR-FL envelope glycoproteins
expressed on the surface of COS-1 cells was measured by the cell-
based ELISA method. CD4-Ig was added at 0.5 mg/ml. Results
are presented as the percentage of binding measured at the final
time point examined. (C) Decay of gp41 HR1 groove exposure for
the indicated envelope glycoproteins at 25uC after pulse-activation
with sCD4. (D) Decay of gp41 HR1 exposure at 25uC and 37uC
after pulse activation by sCD4 (40 mg/ml; 0.8 mM). (E) Decay of
HIV-1(KB9) and HIV-1(89.6) infectivity at 37uC after pulse
activation by sCD4 (40 mg/ml; 0.8 mM).
Found at: doi:10.1371/journal.ppat.1000360.s002 (0.68 MB TIF)
Figure S3 Decay of HIV-1 infectivity at different temperatures
after pulse activation with sCD4. (A) HIV-1(JR-FL) virions were
magnetically immobilized on tissue-culture plates and pulsed with
sCD4 (40 mg/ml; 0.8 mM) for three minutes at 26uC. Samples
were then washed and incubated at the indicated temperatures for
20 min. Cf2Th-CCR5 cells were subsequently added and pelleted
onto the viruses. Two days later, infectivity was measured by
luciferase assays. (B) As a control, viruses were pulsed with buffer,
incubated at the different temperatures, and then Cf2Th-CD4/
CCR5 cells were added. Infectivity was measured two days later
and is presented as mean RLU (6s.e.m.) of three replicate
samples.
Found at: doi:10.1371/journal.ppat.1000360.s003 (0.31 MB TIF)
Figure S4 Decay of infectivity of viruses bearing different HIV-1
envelope glycoproteins. Recombinant, luciferase-expressing virus-
es that contain the indicated envelope glycoproteins were
incubated in culture medium at 37uC for different time periods
and then added to Cf2Th-CD4/CCR5 cells. 48 h later, luciferase
activity in the target cells was measured to estimate the level of
infection. Data are presented as the percentage of infectivity
observed in samples not incubated at 37uC. The inset shows a
comparison between the infectivity half-lives of the non-activated
viruses (measured at 37uC with CD4+CCR5+ cells) and the sCD4-
activated viruses (measured at 26uC with CD42CCR5+ cells).
Found at: doi:10.1371/journal.ppat.1000360.s004 (0.43 MB TIF)
Figure S5 Change in cell-free HIV-1 infectivity after engage-
ment of sCD4. HIV-1(YU2) or HIV-1(JR-FL) virions were
associated with magnetite nanoparticles and then incubated with
the indicated concentrations of sCD4 for different time periods at
26uC. Complexes were then added to confluent cultures of Cf2Th-
CCR5 cells to which a magnetic field was applied. After
incubation for 1 min, cells were washed and further cultured for
two days. As a control, complexes of viruses and magnetite
nanoparticles were incubated with buffer and then adsorbed to
Cf2Th-CD4/CCR5 cells. Results are presented as mean RLU
(6s.e.m.) of three replicate samples.
Found at: doi:10.1371/journal.ppat.1000360.s005 (0.66 MB TIF)
Figure S6 Activation of the HIV-1 envelope glycoproteins by
cell-surface CD4. (A) The abilities of the YU2 and YU2-GS8
envelope glycoproteins to bind different ligands were compared,
using the cell-based ELISA. COS-1 cells transfected with plasmids
expressing the indicated envelope glycoproteins were incubated
with the monoclonal antibodies 39F or IgG1b12 (both at 0.5 mg/
ml), or C34-Ig (20 mg/ml), with or without sCD4 (20 mg/ml;
0.4 mM). Data are presented as mean RLU (6s.e.m.) of two
replicate samples. (B,C) 293T cells transfected with a plasmid
expressing wild-type human CD4 or with the control DKS plasmid
were added to COS-1 cells transfected with plasmids expressing
DKS, wild-type YU2, or the YU2-GS8 envelope glycoproteins.
Cells were pelleted to increase approximation and incubated at
4uC for 75 minutes to allow CD4 engagement. Samples were then
incubated with C34-Ig (20 mg/ml) to measure HR1 groove
exposure (B) or the anti-CD4 antibody sc-70660 (Santa Cruz
Biotechnology) to measure association of the 293T-CD4 cells with
the COS-1 cell monolayer. Antibody binding was detected using
HRP-conjugated antibodies. Data are presented as mean RLU
(6s.e.m.) of two replicate samples. (D) The experiments described
in (B) were repeated, expressing CD4 and the HIV-1 YU2
envelope glycoproteins (or the DKS control) in either COS-1 or
293T cells.
Found at: doi:10.1371/journal.ppat.1000360.s006 (0.56 MB TIF)
Figure S7 Relationship between the amount of transfected
CCR5-expressing plasmid DNA and the density of CCR5 on the
surface of the transfected cells. (A) COS-1 cells cultured in 96-well
plates (2.4610
4 cells per well) were transfected using Effectene
reagent (Qiagen) with the indicated amounts of the pcDNA3.1-
CCR5 plasmid, which expresses the CCR5 gene under the control
of the hCMV-IE promoter. Each well was transfected with the
same total amount of DNA (0.1 mg) by supplementing the
pcDNA3.1-CCR5 plasmid with the DKS plasmid. Two days
later, CCR5 expression was measured using the cell-based ELISA
method with the anti-CCR5 monoclonal antibody 2D7 (1 mg/ml),
detected with a horseradish peroxidase-conjugated goat-anti-
mouse IgG2a antibody. Data are presented as mean RLU
(6s.e.m.) of two replicate samples. (B) Cf2Th cells cultured in
10-cm plates were transfected using Lipofectamine 2000 reagent
(Invitrogen) with the indicated amounts of the pcDNA3.1-CCR5
plasmid. Three days later, cells were analyzed for CCR5
expression with a phycoerythrin-conjugated 2D7 antibody using
an EPICS XL flow cytometer (Beckman-Coulter). Data were
analyzed using WinMDI 2.9 software.
Found at: doi:10.1371/journal.ppat.1000360.s007 (0.18 MB TIF)
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